Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel.
OBJECTIVE
Single nucleotide polymorphisms (SNPs) of certain genes involved in drug metabolism correlate with survival.


METHODS
We evaluated the presence of SNPs in six genes (CYP2C8, GSTT1, GSTP1, MDR1-57, MDR1-62, and ERCC1) and the response rate (RR), time to progression (TTP), and overall survival (OS) of advanced head and neck cancer patients treated with weekly paclitaxel.


RESULTS
SNPs in CYP2C8, MDR1-57, and MDR1-62 genes were more frequent than wild-type genes in our patients. RR was 45% (21/47), and median TTP in responders was 5.1 months. OS for all patients was 5.6 months. Response was higher in SNPs of MDR1-62, MDR1-57, or in two or more accumulated genes than in those with wild-type genes. OS was significantly longer in patients with two or more accumulated SNPs (P = .039).


CONCLUSIONS
Response rate and OS were significantly higher in patients with two or more accumulated SNPs.
Grau
Juan J
JJ
Oncology Department, Institut Clinic de Malalties Hemato-Oncològiques, Hospital Clinic, University of Barcelona, Spain.
Caballero
Miguel
M
Campayo
Marc
M
Jansa
Sonia
S
Vargas
Mauricio
M
Alós
Llucia
L
Monzo
Mariano
M
D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D016001:Confidence Intervals; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004720:Endonucleases / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005819:Genetic Markers / Q000235:genetics*; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000235:genetics; D017239:Paclitaxel / Q000008:administration & dosage*; D010166:Palliative Care; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011336:Probability; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
D005819:Genetic Markers; D009687:Nuclear Proteins; D004720:Endonucleases; D017239:Paclitaxel